Saxagliptin is the generic form of a number of brand- name drugs used to treat type 2 diabetes, including Onglyza and Kombiglyze XR. It has been a source of concern since the FDA approved its use in 2009, despite reservations about clinical trial results. A 2013 study, published in the New England Journal of Medicine subsequently noted a potential for increased risk for “all-cause mortality” with Saxagliptin use. Among these risks is the danger of pancreatitis, a risk factor for pancreatic cancer, which is the fourth most common cause of cancer deaths in the United States.
Saxaglipitin falls within a class of drugs, known as incretin mimetics. These mimic the effect of the body’s natural hormones to lower blood sugar after eating. A number of popular diabetes drugs, including but not limited to Onglyza and Komgiiglyze XR fall within this category.
According to a study published in the medical journal Gastroenterology in February 2011, diabetics who used incretin mimetics were up to 2.7 times more likely to develop pancreatic cancer than diabetics who did not. In February 2013, a study published in JAMA Internal Medicinee found that patients treated with Januvia, an incretin mimetic similar to Onglyza, were twice as likely to be hospitalized with pancreatitis.
READ MORE ONGLYZA AND KOMBIGLYZE XR LEGAL NEWS
Although published reports of Saxagliptin lawsuits based on a diagnosis of pancreatic cancer are still rare, these may be waiting in the wings pending additional clinical research strengthening the link between the drug and the disease. Patients experiencing the symptoms of pancreatitis should certainly alert their health care professionals about the use of any prescription medications to treat diabetes.